Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intergroupe Francophone de Cancerologie Thoracique
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
2nd or 3rd line of non squamous non small cell lung cancer of stage III or IV
Document progression at the time of the inclusion. At least, one previous chemotherapy line with platinum. Patient who had previous treatment with bevacizumab can be included.
Patient with active mutation of EGFR must have had on line of chemotherapy with platinum and one with Tyrosine kinase inhibitor of EGFR.
Patient with ALK rearrangement must have had at least one line of chemotherapy with platinum and one with crizotinib.
You may not be if
Mixed cancer small cells and non small cells or squamous lung cancer.
Central nervous system symptomatic metastasis or requiring immediate cerebral radiotherapy
patient who have had previous treatment with taxane (docetaxel, paclitaxel). Peri-operatory chemotherapy or chemoradiotherapy with taxane allowed if stopped more than 6 months before.
Clareo Health | Paclitaxel-bevacizumab in Advanced Lung Cancer
